AstraZeneca to present new oncology data at upcoming medical congresses

AstraZeneca will be sharing its latest scientific advances in oncology at three major congresses taking place in the US and Europe in the coming weeks.

The company will be attending the American Society of Hematology (ASH) annual meeting in San Diego from December 3rd to 6th, the World Conference on Lung Cancer (WCLC) in Vienna from December 4th to 7th, and the San Antonio Breast Cancer Symposium (SABCS) running from December 6th to 10th.

In total, 50 abstracts – including 15 oral presentations – have been accepted across the ASH, WCLC and SABCS congresses, with products such as Iressa, Tagrisso and Faslodex to be discussed alongside the company's emerging presence in the field of blood cancer.

For example, presentations will be given highlighting the superiority of Tagrisso over standard of care chemotherapy in EGFR T790M mutation-positive non-small cell lung cancer and of Faslodex as a first-line treatment for advanced breast cancer.

New data will also be shared on the safety and efficacy profile of acalabrutinib, a potential best-in-class investigational therapy for a range of B-cell malignancies.

Sean Bohen, executive vice-president for global medicines development and chief medical officer at AstraZeneca, said: "At the end of a memorable year for AstraZeneca in oncology, we will reinforce our leadership in lung and breast cancer research and our growing late-stage pipeline of potential medicines for life-threatening blood cancers."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.